Aberrantly Expressed Embryonic Protein NODAL Alters Breast Cancer Cell Susceptibility to γδ T Cell Cytotoxicity.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2020
Historique:
received: 20 03 2020
accepted: 21 05 2020
entrez: 9 7 2020
pubmed: 9 7 2020
medline: 7 4 2021
Statut: epublish

Résumé

Gamma delta (γδ) T cells kill transformed cells, and increased circulating γδ T cells levels correlate with improved outcome in cancer patients; however, their function within the breast tumor microenvironment (TME) remains controversial. As tumors progress, they begin to express stem-cell associated proteins, concomitant with the emergence of therapy resistant metastatic disease. For example, invasive breast cancers often secrete the embryonic morphogen, NODAL. NODAL has been shown to promote angiogenesis, therapy resistance and metastasis in breast cancers. However, to date, little is known about how this secreted protein may interact with cells in the TME. Herein we explore how NODAL in the TME may influence γδ T cell function. We have assessed the proximity of γδ T cells to NODAL in a cohort of triple negative breast tumors. In all cases in which γδ T cells could be identified in these tumors, γδ T cells were found in close proximity to NODAL-expressing tumor cells. Migration of γδ and αβ T cells was similar toward MDA-MB-231 cells in which NODAL had been knocked down (shN) and MDA-MB-231 scrambled control cells (shC). Furthermore, Vδ1 γδ T cells did not migrate preferentially toward conditioned medium from these cell lines. While 24-h exposure to NODAL did not impact CD69, PD-1, or T cell antigen receptor (TCR) expression on γδ T cells, long term exposure resulted in decreased Vδ2 TCR expression. Maturation of γδ T cells was not significantly influenced by NODAL stimulation. While neither short- nor long-term NODAL stimulation impacted the ability of γδ T cells to kill MCF-7 breast cancer cells, the absence of NODAL resulted in greater sensitivity of targets to γδ T cell cytotoxicity, while overexpression of NODAL conferred resistance. This appeared to be at least in part due to an inverse correlation between NODAL and surface MICA/B expression on breast cancer target lines. As such, it appears that NODAL may play a role in strategies employed by breast cancer cells to evade γδ T cell targeting, and this should be considered in the development of safe and effective γδ T cell immunotherapies.

Identifiants

pubmed: 32636849
doi: 10.3389/fimmu.2020.01287
pmc: PMC7319087
doi:

Substances chimiques

NODAL protein, human 0
Nodal Protein 0
Receptors, Antigen, T-Cell, gamma-delta 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1287

Informations de copyright

Copyright © 2020 Siegers, Dutta, Kang, Huang, Köbel and Postovit.

Références

Cancer Res. 2012 Aug 1;72(15):3851-63
pubmed: 22855743
PLoS One. 2011 Feb 03;6(2):e16700
pubmed: 21304898
Cancer Lett. 2014 Jul 10;349(1):1-7
pubmed: 24727284
Immunity. 2007 Aug;27(2):334-48
pubmed: 17656116
J Immunol. 2019 Jul 15;203(2):311-320
pubmed: 31285310
Clin Exp Immunol. 2010 Aug;161(2):290-7
pubmed: 20491785
Clin Cancer Res. 2016 Dec 1;22(23):5795-5804
pubmed: 27307596
Appl Immunohistochem Mol Morphol. 2019 Sep;27(8):581-583
pubmed: 29517505
Mol Biol Cell. 2011 Dec;22(24):4809-21
pubmed: 22031289
Front Immunol. 2017 Jun 30;8:776
pubmed: 28713391
Mol Immunol. 2006 May;43(12):2002-11
pubmed: 16423401
Front Immunol. 2014 Dec 10;5:632
pubmed: 25540645
Int J Cancer. 2013 Nov;133(9):2133-44
pubmed: 23595559
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Clin Immunol Immunopathol. 1993 Apr;67(1):17-24
pubmed: 8443981
Nat Rev Immunol. 2015 Nov;15(11):683-91
pubmed: 26449179
Int J Biochem Cell Biol. 2013 Apr;45(4):885-98
pubmed: 23291354
Front Immunol. 2018 Jun 15;9:1367
pubmed: 29963058
Cancer Immunol Immunother. 2013 Mar;62(3):571-83
pubmed: 23100099
Breast Cancer Res Treat. 2010 Jul;122(1):135-44
pubmed: 19763820
Science. 2013 Dec 20;342(6165):1432-3
pubmed: 24357284
Oncogene. 2014 Jan 23;33(4):461-73
pubmed: 23334323
Breast. 2019 Nov;48 Suppl 1:S44-S48
pubmed: 31839159
Cancer Immunol Res. 2020 Apr;8(4):530-543
pubmed: 32019779
Cytotherapy. 2011 Jul;13(6):753-64
pubmed: 21314241
Breast Cancer Res Treat. 2005 Sep;93(2):169-75
pubmed: 16187237
Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11906-11915
pubmed: 31118283
Front Immunol. 2014 Dec 08;5:622
pubmed: 25538706
Bone Marrow Transplant. 2007 Jun;39(12):751-7
pubmed: 17450185
Oncoimmunology. 2017 Feb 6;6(3):e1284723
pubmed: 28405516
J Immunol. 2012 Nov 15;189(10):5029-36
pubmed: 23034170
Breast Cancer Res. 2012 May 11;14(3):R75
pubmed: 22577960
Front Immunol. 2019 Nov 22;10:2717
pubmed: 31824502
Oncoimmunology. 2014 Jan 1;3(1):e27572
pubmed: 24734216
J Natl Cancer Inst. 2016 Oct 13;109(1):
pubmed: 27737921
Mol Ther. 2014 Aug;22(8):1416-1422
pubmed: 24895997
Front Immunol. 2018 Jun 15;9:1395
pubmed: 29963061
Transl Res. 2019 Jan;203:88-96
pubmed: 30194922
Blood. 2012 Sep 13;120(11):2269-79
pubmed: 22767497
PLoS One. 2012;7(11):e48237
pubmed: 23144858
Oncoimmunology. 2018 Sep 26;8(1):e1522471
pubmed: 30546961
Br J Cancer. 2011 Sep 6;105(6):778-86
pubmed: 21847128
CMAJ. 2020 Mar 2;192(9):E199-E205
pubmed: 32122974
Cancer Immunol Res. 2018 Apr;6(4):448-457
pubmed: 29358174
Clin Cancer Res. 2014 Nov 15;20(22):5708-19
pubmed: 24833662

Auteurs

Gabrielle M Siegers (GM)

Department of Oncology, University of Alberta, Edmonton, AB, Canada.

Indrani Dutta (I)

Department of Oncology, University of Alberta, Edmonton, AB, Canada.

Eun Young Kang (EY)

Department of Pathology and Laboratory Medicine, Foothills Medical Centre, University of Calgary, Calgary, AB, Canada.

Jing Huang (J)

Department of Oncology, University of Alberta, Edmonton, AB, Canada.

Martin Köbel (M)

Department of Pathology and Laboratory Medicine, Foothills Medical Centre, University of Calgary, Calgary, AB, Canada.

Lynne-Marie Postovit (LM)

Department of Oncology, University of Alberta, Edmonton, AB, Canada.
Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH